Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-340.85%
operating margin TTM
-340.05%
revenue TTM
-576.14 Thousand
revenue per share TTM
-0.02$
valuation ratios | |
|---|---|
| pe ratio | -8.52 |
| peg ratio | -0.07 |
| price to book ratio | 5.92 |
| price to sales ratio | 7.68 |
| enterprise value multiple | -3.59 |
| price fair value | 5.92 |
profitability ratios | |
|---|---|
| gross profit margin | 95.93% |
| operating profit margin | -340.05% |
| pretax profit margin | -336.02% |
| net profit margin | -340.85% |
| return on assets | -58.74% |
| return on equity | -122.12% |
| return on capital employed | -68.95% |
liquidity ratios | |
|---|---|
| current ratio | 6.56 |
| quick ratio | 6.56 |
| cash ratio | 5.91 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 158.66 |
| days of payables outstanding | 2,166.81 |
| cash conversion cycle | -2,008.14 |
| receivables turnover | 2.30 |
| payables turnover | 0.17 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.01 |
| debt equity ratio | 0.01 |
| long term debt to capitalization | 0.01 |
| total debt to capitalization | 0.01 |
| interest coverage | -32.51 |
| cash flow to debt ratio | -13.73 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.22 |
| cash per share | 2.05 |
| operating cash flow per share | -0.22 |
| free cash flow operating cash flow ratio | 1.04 |
| cash flow coverage ratios | -13.73 |
| short term coverage ratios | -51.90 |
| capital expenditure coverage ratio | -27.94 |
Frequently Asked Questions
When was the last time Crescent Biopharma, Inc. (NASDAQ:CBIO) reported earnings?
Crescent Biopharma, Inc. (CBIO) published its most recent earnings results on 11-08-2025.
What is Crescent Biopharma, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Crescent Biopharma, Inc. (NASDAQ:CBIO)'s trailing twelve months ROE is -122.12%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Crescent Biopharma, Inc. (CBIO) currently has a ROA of -58.74%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CBIO's net profit margin stand at?
CBIO reported a profit margin of -340.85% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CBIO's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 6.56 in the most recent quarter. The quick ratio stood at 6.56, with a Debt/Eq ratio of 0.01.